Peptide-Based Molecular Glues for Targeted Protein Degradation
Authors:
- Walaa S. AburayanWAWalaa S. Aburayan
- Ibrahim A. AlradwanIAIbrahim A. Alradwan
- Beshair A. AlsaffarBABeshair A. Alsaffar
- Othman A. AlhazzaaOAOthman A. Alhazzaa
- Fahad A. AlmughemFAFahad A. Almughem
- Abdullah A. AlshehriAAAbdullah A. Alshehri
- Ibtihal S. AlduhaymiIAIbtihal S. Alduhaymi
- Mohannad M. FallatahMFMohannad M. Fallatah
- Meshael AlturkiMAMeshael Alturki
- Hassa A. AlshayaHAHassa A. Alshaya
- Essam A. TawfikETEssam A. Tawfik
Open Access
- 23 September 2026
- journal article
- review article
- Published by MDPI AG in Pharmaceutics
- Vol. 18 (10) , 1208
Abstract
Targeted protein degradation has transformed drug discovery by replacing occupancy-driven inhibition with event-driven removal of disease-causing proteins, opening previously “undruggable” targets, including transcription factors, scaffolding proteins, and intrinsically disordered regions, to therapeutic intervention. Within this landscape, peptide-based molecular glues have emerged as a distinct and underexplored modality, combining the extended, adaptable interaction surfaces of peptides with the mechanistic simplicity of induced-proximity pharmacology. Unlike bifunctional degraders such as PROTACs, which require the concurrent optimization of two linked ligands, peptide molecular glues act through a single engineered interface, stabilizing cooperative ternary complexes between a target protein and an E3 ubiquitin ligase to drive ubiquitination and proteasomal degradation. This review highlights the current understanding of peptide molecular glue biology across five interconnected dimensions: the mechanistic basis of E3 ligase recruitment and cooperative ternary complex formation; rational design strategies spanning sequence selection, structural stabilization, and computational and AI-guided optimization; the structural and biophysical determinants, such as conformational flexibility, interface complementarity, and thermodynamic and kinetic stability, that distinguish productive from non-productive complexes; and emerging therapeutic applications in oncology, hematological malignancy, neurodegeneration, and inflammatory disease, several of which have already reached clinical evaluation. We further examine the comparative advantages of peptide-based architectures, including reduced molecular weight, access to challenging interfaces, and expansion of the addressable E3 ligase repertoire, against persistent translational barriers in proteolytic stability, membrane permeability, immunogenicity, and manufacturability. Taken together, the evidence positions peptide-based molecular glues not as incremental variants of existing degrader platforms, but as a mechanistically distinct therapeutic class capable of substantially widening the druggable proteome.Keywords
This publication has 208 references indexed in Scilit:
- Advances in Hydrocarbon Stapled Peptides via Ring‐Closing Metathesis: Synthetic Strategies, Structural Diversity, and Therapeutic ApplicationsChemBioChem, 2025
- Peptide Drug: Design and Clinical ApplicationsMedcomm, 2025
- The Peptide PROTAC Modality: A New Strategy for Drug DiscoveryMedcomm, 2025
- Drug Discovery Approaches to Target E3 LigasesChemBioChem, 2024
- Connecting Hydrophobic Surfaces in Cyclic Peptides Increases Membrane PermeabilityAngewandte Chemie International Edition, 2020
- Achieving Strong Positive Cooperativity through Activating Weak Non‐Covalent InteractionsAngewandte Chemie International Edition, 2017
- Binding Kinetics in Drug DiscoveryMolecular Informatics, 2016
- Putting Anion–π Interactions Into PerspectiveAngewandte Chemie International Edition, 2011
- Protein–protein interactions as targets for small molecule drug discoveryPeptide Science, 2006
- Protein synthesis and degradation during expression of the temperature‐sensitive defect in ts A1S9 mouse L‐cellsJournal of Cellular Physiology, 1980